Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 17/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 12/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21624833 | 1.00 | NR1H2 (0.54) | NR1H2NR1H3DRD2GPR119 | |
| SCHEMBL31669196 | 0.82 | GPR119 (0.52) | GPR119 | |
| SCHEMBL12367089 | 0.81 | DRD2 (0.59) | NR1H2NR1H3DRD2GPR119 | |
| SCHEMBL22499857 | 0.78 | GPR119 (0.55) | NR1H2NR1H3GPR119 | |
| SCHEMBL22499854 | 0.78 | GPR119 (0.55) | NR1H2NR1H3GPR119 | |
| SCHEMBL16966426 | 0.78 | CA1 (0.48) | NR1H2NR1H3DRD2GPR119 | |
| SCHEMBL1349699 | 0.77 | NOTUM (0.60) | GPR119 | |
| SCHEMBL6488653 | 0.77 | NOTUM (0.60) | GPR119 | |
| SCHEMBL1349702 | 0.77 | NOTUM (0.60) | GPR119 | |
| SCHEMBL19471915 | 0.77 | NOTUM (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020203610-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING RHEUMATOID ARTHRITIS | 日本ケミファ株式会社 | 2020-10-08 | — | — | WO | disclosed |
| WO-2020203609-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | 日本ケミファ株式会社 | 2020-10-08 | — | — | WO | disclosed |
| WO-2020017569-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日本ケミファ株式会社 | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1H | NR1H2 2578/4885NR1H3 3026/4885DRD2 629/4885 |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | NR1H2 1841/4885NR1H3 2100/4885DRD2 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.